Samuel J. Reich - 15 Jul 2024 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SABS	Stock Option (right to buy)	Award	$0	+35,700		$0.000000	35,700	15 Jul 2024	Common Stock	35,700	$2.90	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028.
F2	This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.